Microbiome Therapeutics Market Growth by Type (Fecal Microbiota Transplantation, Microbiome Drugs), Indication (Gastrointestinal and Infectious Disease, Oncology and Autoimmune, Skin Disease) - Global Industry Growth Forecast to 2030

Market Overview

The global microbiome therapeutics market size in 2021 was $314.4 million, and it is expected to advance at a CAGR of 23.1% during the forecast period, to reach $2,036.4 million by 2030. The substantial role that the microbiome plays in gastrointestinal and non-gastrointestinal illnesses makes it a tempting target for new therapies. Moreover, the industry is fueled by the ability of digestive-related therapeutics to overcome inadequacies of conventional treatments, the possibility of these therapeutics to meet unmet requirements of present therapeutic choices, growth in illness dimension, increased strategic activities, involvement of academic institutions, and recognized businesses operating in this field.

The COVID-19 outbreak had a significant negative influence on gut flora-related medicines, causing clinical trial setbacks and forcing a few businesses to optimize their resources and align their goals in order to stay in the market.

Hot Revenue Pocket

• Due to the presence of a number of small, innovative players, there are numerous high-growth opportunities for key stakeholders to acquire businesses that study microbiomes to discover new drugs and drug targets for a variety of indications, including obesity, liver disorders, diabetes, and metabolic disorders. 
• Strategic alliances and collaborations are a top priority for many market leaders, as they work to expand their product pipelines through efficient research and development methods. Also, a number of companies have been involved in partnerships and collaborations over the past two years, to improve their position.
• In order to encourage the use of digestive health-related therapies, businesses are lowering the price of their goods, extending access to state-of-the-art healthcare to a greater section of the populace. As a result, this offers vendors lucrative growth opportunities to increase their revenue and profit.

Fecal Microbial Transplant Holds Major Market Share

The FMT category generated a larger revenue in 2021 in the market, and it is expected to account for more than 84% revenue share by 2030. This is attributed to the surge in the use of fecal microbial transplants and the availability of FMT in capsule form, which have increased the patient acceptability for the treatments of C. difficile infection. As a result, the increasing prevalence of the illness is projected to drive the microbiome therapeutics market demand.

However, the demand for microbiome drugs is predicted to grow at a higher rate over the forecast period. This can be ascribed to the rise in research activities conducted by research institutes in order to uncover additional therapeutic uses for FMT, a strong pipeline, and the creation of cutting-edge and unique medications.

Explore more about this report - Request free sample pages

Rapid Surge in Cases of Gastrointestinal and Infectious Diseases Drives the Market

Microbiome therapeutics are largely used in the treatment of gastrointestinal and infectious diseases, and thus, this category contributed more than 92% of the market share in 2021. Furthermore, a slew of these treatments aimed at gut-related disorders, such as C. diff. infection (CDI), inflammatory bowel disease, and ulcerative colitis, are currently in development and have enormous economic potential in the near future. The other key factors influencing the market growth in this category include the increasing prevalence of infections caused by microbial dysbiosis as a result of antibiotic therapy and the rising number of clinical trials for the creation of target-specific digestive health-related therapies.

Moreover, the oncology and autoimmune category holds a significant share in the market. The effect of designated products on digestive health is being studied in a variety of cancer indications, including pancreatic cancer, melanoma, and others. Furthermore, over 10 medicines are in various clinical trials, which can be used for the treatment of oncology and autoimmune diseases.

Regional Insights

Geographically, the North American microbiome therapeutics market has a high potential for future expansion and growth. Due to the existence of multiple prominent major companies, the region is the largest market for microbiome therapeutics. Also, the rising public–private funding and research grants in digestive-related therapies have hastened the adoption of these treatments in both the U.S. and Canada.

The U.S. dominates the North American market, owing to the rise in research and development activities in the field of regenerative medicine, as well as strong government backing. Moreover, the industry in the country is expected to grow rapidly in the future, driven by the progress of key products, which are in the most advanced stages of development, as well as the expected positive outcomes of clinical studies for several potential therapeutics targeting various indications, including immune health, skin disorders, oncology, and neurodegenerative diseases.

In addition, the commercialization of cutting-edge therapeutics for the treatment of numerous diseases is increasing in Europe. The industry in the region is expanding, as a result of the rising healthcare spending and the increasing research activities to create novel products based on the microbiome. The expansion of the clinical research sector along with product approvals and commercialization in various EU nations is projected to drive the demand for these therapies in Europe in the approaching years.

France is home to renowned scientific and research centers, which are fostering innovation for the sake of humanity. By implementing measures that make it easier for start-ups and small-to-medium firms to enter the country's biopharmaceutical industry, the nation promotes technological developments even more. The acceptance of innovative medications has also been made easier by the country's advantageous reimbursement policies, which has sped up the development of the market in France.

On the other hand, the APAC is the fastest-growing market, registering a CAGR of more than 23%, from 2021 to 2030. The main elements driving the industry growth include rising healthcare spending, increasing government support for accelerating research and clinical trials, and surging awareness of therapeutic goods. Additionally, the development of these treatments in the APAC healthcare sector is strongly supported by technical developments in the infrastructure and considerable investments in this sector. Also, the regional market is expanding as a result of the growing geriatric population, surging prevalence of chronic diseases, rising need for effective and cutting-edge treatment alternatives, and key businesses operating in the region.

The Japanese government's growing concern for enhancing public health conditions and the healthcare system, which can support the adoption of novel technologies and cutting-edge medicines in the country. Thus, this factor will boost the microbiome therapeutics market growth in Japan.

In addition, the LATAM and MEA markets are expected to rise in the coming years. The most significant factor driving the market in these regions is the surging importance of digestive health-related therapies in key MEA and LATAM nations, together with the growing awareness of these treatments. Additionally, the rising business investment in research and development, as well as funding from public and private organizations, contributed to the market expansion for gut-related treatments in these areas.

To Increase Market Share, Companies Involved in Several Strategic Developments

Organizations can expand their present portfolios of microbiome therapeutics in the market through several strategic techniques. The contributors use synergistic activities and mergers and acquisitions as some of their techniques. To make an impression, most businesses also develop new products, broaden their administration portfolios, and enter into untapped markets. For instance:

• In February 2022, the FDA approved 4D pharma plc's two live biotherapeutics (LBPs) MRx0005 and MRx0029, which are indicated for the management of Parkinson's disease.
• In November 2021, Bacthera partnered with Seres Therapeutics Inc., for the commercial manufacture of its lead candidate SER-109, indicated for the treatment of recurrent C. difficile infection.

Top Players in the Microbiome Therapeutics Market Are:

• 4D pharma plc
• Seres Therapeutics Inc.
• SANOFI S.A.
• Enterome
• Destiny Pharma Plc
• Taisho Pharmaceutical Holdings Co. Ltd.
• AOBiome LLC
• Ferring International Center S.A.
• Pendulum Therapeutics Inc.
• YSOPIA Bioscience

Market Size Breakdown by Segment

The report offers a comprehensive segmentation analysis along with revenue estimation for the period 2017-2030.

Based on Type

• Fecal Microbiota Transplantation (FMT)
• Microbiome Drugs

Based on Indication

• Gastrointestinal and Infectious Disease
• Oncology and Autoimmune
• Skin Disease

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Spain
  • Italy
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • South Africa
  • Saudi Arabia